Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. The Talisman device aims to treat patent foramen ovale (PFO) patients who have had a stroke and are at ...

Abbott has launched its Amplatzer Tailsman PFO Occlosion System in Europe. The device is designed to treat people with a patent foramen ovale (PFO) who have had a stroke and are at risk of having ...

St. Luke's Health-Memorial Hospital Lufkin recently announced a significant advancement in cardiovascular care, becoming the first and only hospital in Deep East Texas to successfully perform a ...

Please provide your email address to receive an email when new articles are posted on . Supraventricular arrhythmias may be underestimated in patients who have received percutaneous patent foramen ...

While other device-based closures have demonstrated notable rates of atrial fibrillation (5.7–6.6%) and device-related adverse events, the NobleStitch™ system's fully suture-mediated approach ...

The population of patients undergoing patent foramen ovale (PFO) closure in the US doesn’t match those of the clinical trials that formed the basis of the US Food and Drug Administration’s approval of ...